Clinical Trials · NCT04997317
Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide
- Phase
- Phase 1/Phase 2
- Recruitment status
- Recruiting
- Sponsor
- University Hospital, Basel, Switzerland
- Enrollment
- 18
- Start date
- Apr 2021
- Locations
- 1 site, Switzerland
- Primary endpoint
- Change in Tumour-to-dose limiting organ dose ratio T-to-bone marrow: Therapeutic Index (Phase 0)